Fighting Melanoma, 05 Oct 2016 Abstract: On October 27, 2015, talimogene laherparepvec (T-VEC), a first in class intralesional oncolytic virotherapy, was…
Fighting Melanoma, 05 Oct 2016 On October 27, 2015, talimogene laherparepvec (T-VEC), a first in class intralesional oncolytic virotherapy, was granted the US…